Zacks Investment Research cut shares of Fibrocell Science (NASDAQ:FCSC) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning.
According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
Separately, HC Wainwright set a $6.00 price target on shares of Fibrocell Science and gave the stock a buy rating in a report on Tuesday, January 30th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Fibrocell Science presently has an average rating of Hold and a consensus price target of $3.94.
In related news, major shareholder Randal J. Kirk purchased 2,727,273 shares of the stock in a transaction dated Monday, December 11th. The stock was bought at an average cost of $0.77 per share, for a total transaction of $2,100,000.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 2.10% of the stock is currently owned by corporate insiders.
Large investors have recently made changes to their positions in the company. FNY Partners Fund LP acquired a new position in shares of Fibrocell Science during the fourth quarter worth $129,000. Parametric Portfolio Associates LLC increased its holdings in shares of Fibrocell Science by 264.0% during the second quarter. Parametric Portfolio Associates LLC now owns 48,259 shares of the company’s stock worth $194,000 after buying an additional 35,000 shares in the last quarter. Anson Funds Management LP acquired a new position in shares of Fibrocell Science during the fourth quarter worth $287,000. Armistice Capital LLC acquired a new position in shares of Fibrocell Science during the fourth quarter worth $393,000. Finally, Sabby Management LLC acquired a new stake in Fibrocell Science in the fourth quarter valued at $733,000. Institutional investors own 43.00% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Fibrocell Science (FCSC) Downgraded by Zacks Investment Research” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.com-unik.info/2018/02/18/fibrocell-science-fcsc-downgraded-by-zacks-investment-research.html.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.